A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

Conversations with over a dozen college students across the US revealed fears of developing an over-reliance on AI.

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other ...